Last reviewed · How we verify
NCT04626765
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
EARLY_PHASE1 trial testing CD19 CAR-T in Childhood Acute Lymphoblastic Leukemia in 50 participants. Status unknown.
30 March 2023
Quick facts
| Lead sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 April 2020 |
| Primary completion | 30 March 2023 |
| Estimated completion | 30 May 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19 CAR-T
- CD22 CAR-T — full drug profile →
- CD 19+22 — full drug profile →
- Fludarabine (FLUDARABINE) — full drug profile →
- Cyclophosphamide (cyclophosphamide) — full drug profile →
Conditions studied
- Childhood Acute Lymphoblastic Leukemia — all drugs for Childhood Acute Lymphoblastic Leukemia →
Sponsor
Hebei Senlang Biotechnology Inc., Ltd. — full company profile →
Who can join
Adults 1 to 18, any sex, with Childhood Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, CAR-T will be administered to children with acute lymphoblastic leukemia to explore the effect of CAR-T intervention time on the duration of complete remission and further verify the long-term safety and efficacy of CAR-T treatment.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting CD22 for the Treatment of B-Cell Malignancies.
Shah NN, Sokol L. · · 2021 · cited 42× · PMID 34262884 · DOI 10.2147/itt.s288546 -
Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia.
Pastorczak A, Domka K, Fidyt K, Poprzeczko M, et al · · 2021 · cited 42× · PMID 33810515 · DOI 10.3390/cancers13071536 -
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255
Verify or expand the search:
- PubMed search for NCT04626765
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CD19 CAR-T
Trials testing the same drug.
- NCT04546893 — Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia · NA · unknown
- NCT04447547 — Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma · NA · unknown
- NCT04626739 — CAR-T Cells in Treating Patients With Relapsed or Refractory NHL · EARLY_PHASE1 · unknown
- NCT04626726 — Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation · EARLY_PHASE1 · unknown
Other recruiting trials for Childhood Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT07071051 — Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Pat · recruiting
- NCT06575296 — Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant · Phase 1 · recruiting
Other Hebei Senlang Biotechnology Inc., Ltd. trials
Trials by the same sponsor.
- NCT07435779 — Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study · EARLY_PHASE1 · recruiting
- NCT07421856 — Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. · Phase 1, PHASE2 · not yet recruiting
- NCT07244380 — Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. · Phase 2 · not yet recruiting
- NCT07161193 — Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases · Phase 1, PHASE2 · not yet recruiting
- NCT07244406 — Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04626765 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hebei Senlang Biotechnology Inc., Ltd.
- Last refreshed: 13 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04626765.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing